Alamar Biosciences (Nasdaq: ALMR) announced that its NULISA™ precision proteomics platform will appear in more than 140 posters and sessions at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12‑15, reflecting broad research use in Alzheimer’s and related dementias.
The company will host a workshop, “Beyond p-tau217: Expanding Alzheimer’s Insights with Multiplex Protein Profiling,” on July 14, 1:20–2:00 PM BST, highlighting eMTBR-Tau and BD-pTau217 assays, their use alongside over 220 disease-related proteins, and applications across presymptomatic to diagnosed populations.
Loading…
Loading translation…
AI-generated analysis. How Rhea-AI works. Not financial advice.
Extensive AAIC 2026 exposure, with NULISA featured in more than 140 presentations and measuring over 220 proteins, underscores accelerating adoption. Prior eMTBR-Tau launch saw a modest decline, and investors may watch how broader clinical validation and funding needs evolve.
AAIC 2026 NULISA presentations more than 140 Posters and sessions featuring NULISA platform at AAIC 2026
Increase vs prior AAIC over four times Growth in NULISA-related posters and presentations versus previous AAIC
AAIC 2026 dates July 12–15 Alzheimer’s Association International Conference in London
Workshop time 1:20–2:00 PM BST Alamar workshop during AAIC on Tuesday, July 14
Proteins on NULISAseq panel more than 220 Disease-related proteins measured alongside eMTBR-Tau and BD-pTau217
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Biomarker assay launch | Positive | -1.7% | Launch of first multiplexed eMTBR-Tau blood immunoassay for Alzheimer’s research. |
| May 08 | 1Q26 earnings report | Positive | +1.3% | Q1 2026 revenue doubled year-over-year with improved gross margin and IPO proceeds. |
| May 05 | Conference participation | Neutral | -0.3% | Announcement of presentation slot at BofA Securities 2026 Healthcare Conference. |
| Apr 20 | NASDAQ listing | Positive | +0.0% | NASDAQ listing with IPO pricing, opening trade, and disclosed market capitalization. |
Pattern Detected
Recent news flow shows a mix of aligned and divergent price reactions, with no consistent pattern around product or listing announcements.
Short Interest
3.69% of float
0% 15% 30%+
low as of 2026-06-15 Days to cover: 11.46
Reported short interest appears relatively low, suggesting limited short-squeeze risk but also moderating any volatility driven purely by short covering.
bd-ptau217 medical
“new data generated on Alamar’s NULISA platform, specifically on its eMTBR-Tau and BD-pTau217 assays”
bd-ptau217 is a blood-based laboratory measure of tau protein that is phosphorylated at the amino acid position 217, used as a biomarker for Alzheimer’s disease and related neurodegeneration. Think of it like a specific smoke detector reading in the blood that signals a particular type of brain change; it matters to investors because it can serve as a diagnostic tool, a way to monitor disease progression, and an objective endpoint in clinical trials for therapies.
ptau-217 medical
“goes beyond pTau-217 to show what’s possible when you can measure tau pathology”
A specific form of the tau protein that carries a phosphate group at the 217th amino acid position and is measured in blood or cerebrospinal fluid as a biomarker of Alzheimer’s-related brain changes. Think of it like a smoke alarm reading that helps detect and track the biological signals of Alzheimer’s disease before symptoms are obvious. Its levels matter to investors because they influence the development, approval, and commercial demand for diagnostics and therapies targeting neurodegeneration.
multiplex protein profiling technical
“the field has embraced multiplex protein profiling with NULISA for Alzheimer’s research”
A lab technique that measures many different proteins at the same time from a single sample, using assays or sensors arranged to detect multiple targets in parallel. Think of it like taking a group photo of proteins instead of separate headshots: it gives a broad snapshot of biological activity quickly and efficiently. Investors care because the method can speed biomarker discovery, diagnostic tests, and drug development, which can affect the value and competitive position of biotech and diagnostics companies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging
FREMONT, Calif., July 10, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that its NULISA™ platform will be featured in more than 140 poster and session presentations at the Alzheimer’s Association International Conference (AAIC), taking place July 12-15 in London. The volume of data reflects widespread adoption of NULISA and ARGO™ HT technology among researchers studying Alzheimer’s and related dementias.
“With more than 140 posters and presentations featuring NULISA, over four times the number at the previous AAIC, we’re seeing just how quickly the field has embraced multiplex protein profiling with NULISA for Alzheimer’s research,” said Steve Williams, MD, PhD, chief scientific officer at Alamar. “Our workshop this year goes beyond pTau-217 to show what’s possible when you can measure tau pathology, neuroinflammation, and neurodegeneration markers together in one workflow.”
Alamar will host a workshop titled, “Beyond p-tau217: Expanding Alzheimer’s Insights with Multiplex Protein Profiling” during AAIC on Tuesday, July 14, 1:20-2:00 PM BST. The program will showcase new data generated on Alamar’s NULISA platform, specifically on its eMTBR-Tau and BD-pTau217 assays. Highlights include:
- eMTBR-Tau and BD-pTau217 represent two of the most specific blood-based indicators of Alzheimer’s disease identified to date and were measured alongside more than 220 disease-related proteins on a single NULISAseq™ panel.
- Evidence that measuring BD-pTau217 and eMTBR-Tau improves discrimination across the Alzheimer’s continuum compared to single-analyte pTau-217 measurement alone and data supporting the use of combined amyloid and tau biomarkers to enable earlier detection and more precise disease staging.
- Applications of the NULISA platform across presymptomatic, prodromal, and diagnosed Alzheimer’s populations.
“The ability to measure eMTBR-Tau and BD-pTau217 alongside a broad panel of CNS-relevant proteins in a single workflow gives us a resolution on tau pathology and disease staging that single-marker assays can’t match. We believe this kind of multiplex data is what will move the field past pTau-217 as the default readout,” said Thomas K. Karikari, PhD, Director of the Biomarker and Neurogenetics Core at the University of Pittsburgh.
The Alzheimer’s Association International Conference is the world’s premier forum for the scientific community focused on dementia and Alzheimer’s research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. Alamar will be exhibiting at Booth 530 throughout the conference.
See here for a full list of posters and presentations featuring NULISA data at AAIC 2026.
About Alamar Biosciences, Inc.
Alamar Biosciences is a life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform, along with the ARGO HT System, works alongside the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of Alamar Biosciences’ eMTBR-Tau and BD-pTau217 assays, the potential impact of multiplex protein profiling in Alzheimer’s disease research and Alamar Biosciences’ participation at an upcoming conference. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor Contact
investors@alamarbio.com
Media Contact
media@alamarbio.com
FAQ
What did Alamar Biosciences (NASDAQ: ALMR) announce about NULISA data at AAIC 2026?
Alamar Biosciences announced that its NULISA platform will be featured in more than 140 posters and sessions at AAIC 2026. According to Alamar Biosciences, this reflects widespread adoption of NULISA and ARGO HT technology in Alzheimer’s and dementia research presented in London.
When is the Alamar Biosciences AAIC 2026 workshop on eMTBR-Tau and BD-pTau217?
Alamar Biosciences will host its AAIC 2026 workshop on Tuesday, July 14, from 1:20–2:00 PM BST. According to Alamar Biosciences, the session will focus on multiplex protein profiling and new data from eMTBR-Tau and BD-pTau217 assays for Alzheimer’s detection and staging.
What are eMTBR-Tau and BD-pTau217 biomarkers presented by Alamar Biosciences (ALMR)?
eMTBR-Tau and BD-pTau217 are described as among the most specific blood-based indicators of Alzheimer’s disease identified to date. According to Alamar Biosciences, they were measured alongside more than 220 disease-related proteins on a single NULISAseq panel for Alzheimer’s research.
How does Alamar Biosciences say NULISA improves Alzheimer’s disease staging?
According to Alamar Biosciences, measuring BD-pTau217 and eMTBR-Tau together improves discrimination across the Alzheimer’s continuum versus single-analyte pTau-217. The company reports data supporting combined amyloid and tau biomarkers for earlier detection and more precise staging across presymptomatic, prodromal, and diagnosed populations.
Where will Alamar Biosciences (ALMR) be exhibiting during AAIC 2026?
Alamar Biosciences will be exhibiting at Booth 530 during the Alzheimer’s Association International Conference 2026 in London. According to Alamar Biosciences, attendees can visit the booth for more information and access the full list of NULISA-related posters and presentations.
What is the focus of Alamar Biosciences’ NULISA multiplex protein profiling for Alzheimer’s?
Alamar Biosciences’ NULISA multiplex protein profiling focuses on measuring tau pathology, neuroinflammation, and neurodegeneration markers in one workflow. According to Alamar Biosciences, this approach aims to move beyond pTau-217 as a default readout by delivering richer Alzheimer’s biomarker data.
